Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
INTESTINE: Gemigliptin/Metformin vs Glimepiride/Metformin in Obese T2D
NCT02609815Completed
- Sponsor
- Seoul National University Bundang Hospital
- Start
- Nov 2015
- Primary completion
- Mar 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, open-label trial of gemigliptin in type 2 diabetes mellitus (T2DM), sponsored by Seoul National University Bundang Hospital. Primary endpoint: Gut microbiota composition change from baseline at 24 weeks. Started Nov 2015; status: completed.
02
Drugs
gemigliptin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT02609815.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02609815.